ImClone Systems Incorporated Patent applications |
Patent application number | Title | Published |
20090306348 | Antibody Formulation - The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stabile formulation of antibodies that are prone to non-enzymatic fragmentation at the hinge region. In a further embodiment, the invention provides methods of stabilization of antibodies comprising lyophilizing an aqueous formulation of an antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. In one embodiment, the present invention provides methods of stabilization of anti-VEGFR antibodies comprising lyophilizing an aqueous formulation of an anti-VEGFR antibody. The formulations can be lyophilized to stabilize the anti-VEGFR antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. | 12-10-2009 |
20090297509 | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis. | 12-03-2009 |
20090142358 | HUMAN ANTIBODIES SPECIFIC TO KDR AND USES THEREOF - The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal. | 06-04-2009 |
20090136510 | Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof - The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer. | 05-28-2009 |
20090110678 | RECEPTOR ANTAGONISTS FOR TREATMENT OF METASTATIC BONE CANCER - The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents. | 04-30-2009 |
20090099339 | ANTIBODY AND ANTIBODY FRAGMENTS FOR INHIBITING THE GROWTH OF TUMORS - Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors. | 04-16-2009 |
20090053241 | PDGFRbeta-specific inhibitors - The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs. | 02-26-2009 |
20090048301 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS - The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture. | 02-19-2009 |